- Partnerships
Strategic Partnerships with Development Teams
Altreos collaborates with organizations that require specialized CNS and abuse-potential expertise to complement their internal capabilities. Partnerships are structured to provide clear roles, defined deliverables, and direct access to senior scientists.
Altreos works alongside:
- Biopharmaceutical companies developing CNS-active or abuse-liable products
- CROs and specialized research units that need senior CNS and abuse-liability input
- Academic and hospital-based investigators leading CNS and substance-use studies
- Organizations developing new clinical models, methodology, or educational programs in CNS and addiction science
- Partnerships
How Altreos Works With Partners
Partnerships are designed to be predictable and sustainable while preserving access to senior expertise.
Typical features:
- Defined Scope And Role
Clear description of Altreos’ responsibilities, decision points, and deliverables across the program or initiative. - Direct Access to Senior Scientists
Work is led and performed by PhD-level partners with deep CNS, clinical pharmacology, and abuse-liability experience. - Integrated With Partner Processes
Collaboration can align with existing governance, review committees, and documentation templates, rather than creating parallel workflows. - Longitudinal Involvement
Continued engagement from early design through study completion, submission, and post-marketing questions, ensuring continuity of scientific and regulatory rationale. - Evidence-Based Output
Recommendations, analyses, and documents are anchored in current data, guidance, and methodological standards relevant to CNS and abuse-potential programs.
Partnership models may include retainer-based advisory support, program-specific scopes, or discrete work packages linked to key milestones such as study design, regulatory meetings, or submission preparation.